4World Health Organization. Guidelines for surveillance of drug resistance in tuberculosis. Geneva: World Health Organiza tion, 2009.
5Yew W*vV, Chan CK, Chan CH, et al. Outcomes of patients with multidrng-resistant pulmonary tuberculosis treated with ofloxaein/levofloxaciweoniaining regimens. Chest, 2000, 117 (3) : 744-751.
6Periman DC,EI Sadr WM, Heifers LB,et al. Susceptibility to levofloxacin of Mycobacte*'itum tuberculosis isolates from pa- tients with HIV-related tuberculosis and characterization of a strain with levofloxacin monoresistance. AIDS, 1997,11 (12) : 1473-1478.
7Devasia RA, Blaekinan A, Gebretsadik T, et al. Fluoroquino- lone resistance in Mycobacte*'ium tubere.Mosis: the effect of duration and timing of fluoroquinolone exposure. Am J Respir Crit Care Med, 2009,180(4) : 365 370.
8Ginsburg AS, HooPer N, Parrish N, et al. Fluoroquinolone resistanee in patients with newly diagnosed tuberculosis. Clin Infect Dis,2003,37(ll) : 1448 1452.
9Agrawal D, Udwadia ZF, Rodriguez C, et al. Increasing inci denee of Fluoroquinolone-resistant Mytx~bacterium tuberculosis in Mumbai, India. Int J Tuberc Lung Dis, 2009,13 ( 1 ) : 79 83.
